2021
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2021, 22: 407-414. PMID: 33656660, PMCID: PMC8068681, DOI: 10.1007/s40257-021-00591-x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAgedAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleFemaleFollow-Up StudiesGelsHumansMaleMechlorethamineMiddle AgedMycosis FungoidesNeoplasm StagingProspective StudiesQuality of LifeSeverity of Illness IndexSkin NeoplasmsTreatment OutcomeUnited StatesConceptsHealth-related qualityMycosis fungoides cutaneous T-cell lymphomaCutaneous T-cell lymphomaChlormethine gelT-cell lymphomaMechlorethamine gelMonths post-treatment initiationEfficacy-evaluable patientsSkin-directed therapiesPrimary efficacy endpointProportion of patientsPatient-completed questionnairesPost-treatment initiationSkindex-29 scoresImportant therapeutic optionBody surface areaSkindex-29 questionnaireAssessment of responseReal-world studyPROVE StudyEfficacy endpointTopical corticosteroidsAdult patientsClinic visitsMycosis fungoides
2013
Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J, Cowper S, Moss J, Girardi M. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal Of Drugs In Dermatology 2013, 12: 487-9. PMID: 23652902.Peer-Reviewed Case Reports and Technical NotesConceptsExcimer laser therapyOral bexaroteneLaser therapyMycosis fungoides lesionsMinimal side effectsMF plaquesLocal erythemaMycosis fungoidesTreatment regimenCutaneous lesionsMF lesionsHistologic resolutionSide effectsTherapyBexaroteneLesionsUltraviolet ARegimenPUVAPatientsTreatmentPlaquesCase experienceFungoidesErythema
2009
Primary Cutaneous Aspergillosis in an Immunocompetent Patient: Successful Treatment with Oral Voriconazole
CRAIGLOW B, HINDS G, ANTAYA R, GIRARDI M. Primary Cutaneous Aspergillosis in an Immunocompetent Patient: Successful Treatment with Oral Voriconazole. Pediatric Dermatology 2009, 26: 493-495. PMID: 19689543, DOI: 10.1111/j.1525-1470.2009.00971.x.Peer-Reviewed Original Research